Related Experiment Video

Updated: May 31, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Anticancer activity of thymoquinone in breast cancer cells: possible involvement of PPAR-γ pathway

Chern Chiuh Woo1, Ser Yue Loo, Veronica Gee

  • 1Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

Biochemical Pharmacology
|June 18, 2011
PubMed

Insights

Thymoquinone (TQ), from Nigella sativa, shows anticancer effects on breast cancer by inducing apoptosis and reducing cell migration. This study reveals TQ activates the PPAR-γ pathway, suggesting a new therapeutic target for breast cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Thymoquinone (TQ), derived from Nigella sativa, possesses known antioxidant, anti-inflammatory, and anti-tumor properties.
  • The precise mechanisms underlying TQ's anti-tumor effects, particularly in breast cancer, remain incompletely elucidated.
  • The potential role of the Peroxisome Proliferator-Activated Receptor gamma (PPAR-γ) pathway in TQ's action is under investigation.

Purpose of the Study:

  • To investigate the anticancer effects of Thymoquinone (TQ) on breast cancer cells.
  • To explore the potential involvement of the PPAR-γ activation pathway in TQ's anti-cancer mechanisms.
  • To assess TQ's impact on breast cancer cell proliferation, apoptosis, and invasiveness.

Main Methods:

  • Cell proliferation assays and cytotoxicity assessments with combination therapy (doxorubicin, 5-fluorouracil).
  • Flow cytometry for sub-G1 accumulation and annexin-V staining to detect apoptosis.
  • Caspase activity assays, cell migration, and invasion assays.
  • PPAR-γ activity assays, gene expression analysis (Bcl-2, Bcl-xL, survivin), and molecular docking studies.

Main Results:

  • TQ demonstrated significant anti-proliferative effects on breast cancer cells and enhanced cytotoxicity when combined with standard chemotherapeutics.
  • TQ induced apoptosis, evidenced by increased sub-G1 phase accumulation and positive annexin-V staining, and activated caspases 8, 9, and 7.
  • TQ inhibited cell migration and invasion, increased PPAR-γ activity, and downregulated key survival genes (Bcl-2, Bcl-xL, survivin).
  • Molecular docking confirmed TQ's interaction with critical residues in the PPAR-γ ligand-binding pocket, suggesting it acts as a PPAR-γ ligand.

Conclusions:

  • Thymoquinone exhibits potent anticancer properties against breast cancer cells, including induction of apoptosis and inhibition of migration/invasion.
  • TQ modulates the PPAR-γ activation pathway, suggesting a novel mechanism for its anti-tumor effects.
  • These findings highlight Thymoquinone's potential as a therapeutic agent or preventative strategy for breast cancer, possibly via PPAR-γ modulation.

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...